http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110403952-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_65cf9c15c2458dbcc36615bf7e04155c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb7e33621aeb12461010672cf0d23319 |
| publicationDate | 2019-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-110403952-A |
| titleOfInvention | Application of miR-146a in the inhibition and treatment of primary liver cancer |
| abstract | The invention discloses the application of miR-146a in inhibiting and treating primary liver cancer. At the cell and animal levels, miR‑146a inhibits the expression of NF‑κB and further inhibits the expression of the proto-oncogene c‑Myc, thereby inhibiting tumors. At present, the common treatment methods for the treatment of advanced liver cancer include intervention, radiofrequency ablation and chemotherapy, but the curative effect is not good. miR‑146a can be used as a potential target for the treatment of liver cancer, as a useful supplement to the current treatment of advanced liver cancer. |
| priorityDate | 2019-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 204.